Efficacy of PEG-IFN alpha-2a in the treatment of chronic Hepatitis B

Efficacy of PEG-IFN alpha-2a in the treatment of chronic Hepatitis B - Treatment with Peg-interferon alpha-2a for chronic hepatitis B

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014271

Enrollment

100

Registered

2014-06-16

Start date

2013-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

PEG-IFN alfa2a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Hepatitis B

Exclusion criteria

Exclusion criteria: 1.History of IFN or Nucleic acid analog use within 6 months 2.autoimmune hepatitis, alcoholic hepatitis, cirrhosis, hepatic failure 3.pregnacy, nursing mom 4.interstitial pneumonia 5.severe bone-marrow dysfunction, severe renal dysfunction, severe cardiac dysfunction, severe respiratory failure 6.HCC or other cancer 7.total bilirubin>2.0mg/dL,prothrombin activity<60%, Albumin<3.6 g/dL(more than 2 points) 8.Allergy for sitagliptin, nateglinide, liraglutide and exenatide 9.depression 10.Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Clinical stability rate after the treatment	—

Secondary

Measure	Time frame
Factors associated with clinical stabilization	—

Countries

Japan

Contacts

Public ContactMatsui Takeshi

Nagoya City University Graduate School of Medical Sciences Virology unit

mtake0402@gmail.com052-842-8191

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026